The Hong Kong stock market opened on April 24th with the Hang Seng Index and Hang Seng Tech Index initially lower before turning positive. Among the early gainers, CRO (Contract Research Organization) concept stocks showed notable upward momentum.
A key exchange-traded fund tracking this sector, the Hong Kong Innovative Drug ETF (159567), opened higher. At the time of reporting, it was up 3.72%, with its turnover rapidly exceeding 166 million yuan. Leading the gains among its constituent stocks were companies like Asymchem Laboratories, which surged over 10%. Other significant gainers included RemeGen, Akeso, Innovent Biologics, Ascentage Pharma, CMS Pharma, Junshi Biosciences, and 3SBio.
Capital Flows and Market Performance
According to data from Wind Financial Terminal, the Hong Kong Innovative Drug ETF (159567) has seen net capital inflows on seven of the past ten trading days. This sustained interest has resulted in cumulative net inflows of over 280 million yuan during this period.
This ETF closely tracks the performance of the Hong Kong Stock Connect Innovative Drug Index (987018). This index is designed to reflect the operational characteristics of listed companies within the biotech industry that are part of the Hong Kong Stock Connect scheme.
Broader Market Sentiment and Research Focus
Market news from Caixin indicates that since the beginning of April, over 400 listed companies have received research visits from securities firms. In terms of sector distribution, the electronics industry led with 60 companies being researched, making it the most popular sector. The healthcare and biopharmaceutical sector also attracted significant attention, with 46 companies receiving analyst visits.
Institutional analysts suggest that, from an investment perspective, a confluence of factors could lead to an expansion in valuations for the electronics sector. They advise paying close attention to the window for sector allocation amidst external uncertainties. For the healthcare and biopharmaceutical sector, the recommended focus is on the investment value present in innovative drug development.
Global and Domestic Funding Landscape for Innovative Drugs
Analysis from Guotou Securities points to a recovery in global and U.S. venture capital and private equity (VC&PE) funding for innovative drugs in 2024, showing a return to positive growth. The first quarter of 2025 showed a marked improvement in the year-on-year growth rate of global VC&PE funding for innovative drugs. Data from Crunchbase reveals that in Q1 2025, global funding increased by 20.57% compared to the same period last year. However, funding in the U.S. and China saw decreases of 4.99% and 4.05%, respectively.
The Expanding Horizon for Innovative Medicine
A research report from Industrial Securities highlights the expanding global market for innovative drugs. This growth is driven by breakthroughs in new technological fields, the development of more effective medicines, a broader patient population benefiting from these drugs, and extended treatment durations.
On the domestic policy front in China, the general direction is supportive. Drugs demonstrating truly differentiated innovation are likely to receive better policy support across multiple stages. This includes the regulatory approval pathway, reimbursement through national medical insurance, hospital adoption, and enjoying a favorable competitive landscape.
For the internationalization pathway, products with genuinely differentiated global efficacy have a clear route to market. Chinese-developed innovative drugs, particularly in areas like TCEs (T Cell Engagers), bispecific antibodies, and Antibody-Drug Conjugates (ADCs), continue to produce candidates with Best-in-Class (BIC) potential on a global scale. The long-term outlook remains positive for companies possessing differentiated innovation capabilities and a pipeline of products with global BIC potential.
The report concludes that China's innovative drug sector has entered its "3.0 Era." Investors are advised to focus on three main themes: genuine innovation, technological self-sufficiency, and domestic demand.
👉 Track the latest biotech investment trends
Frequently Asked Questions
What are CRO concept stocks?
CRO concept stocks refer to publicly traded companies operating in the Contract Research Organization industry. These firms provide support services to the pharmaceutical, biotechnology, and medical device industries, such as clinical trial management and drug development assistance. Their stock prices often move together based on sector-wide news and trends.
What does the Hong Kong Innovative Drug ETF (159567) track?
This ETF is designed to track the performance of the Hong Kong Stock Connect Innovative Drug Index (987018). This index measures the performance of companies in the biotech and innovative drug sector that are accessible through the Hong Kong Stock Connect program, offering investors targeted exposure to this specific market segment.
Why is there increased interest in the innovative drug sector?
Interest is driven by several factors, including breakthroughs in new drug technologies (like ADCs and bispecific antibodies), supportive government policies in China for truly innovative products, and the increasing global market potential for effective new treatments that benefit larger patient populations over longer timeframes.
What is meant by "China's innovative drug 3.0 Era"?
This term signifies a new phase of maturity for China's pharmaceutical industry. It moves beyond generic drugs and me-too products into a period focused on developing truly original, globally competitive drugs with Best-in-Class potential. This era is characterized by advanced research, international collaboration, and a strategic emphasis on innovation and self-reliance.
How can investors track capital flows into sector-specific ETFs?
Investors can monitor data from financial information terminals like Wind, which provide details on daily net inflows and outflows for specific ETFs. Observing trends over time, such as multiple days of net inflows, can indicate sustained investor confidence in a particular sector or theme.
What are the main investment themes in China's biopharma sector?
Current analysis suggests focusing on three core investment lines: companies demonstrating strong "Innovation" capabilities, those achieving "Self-sufficiency" in key technologies to mitigate supply chain risks, and firms well-positioned to benefit from growing domestic demand ("Internal demand") within China's healthcare market.